Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

Gilead will pay $202 million to resolve claims that it paid kickbacks to healthcare providers in the form of honoraria, meals ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Pharmaceutical firm Gilead has admitted paying hundreds of thousands of dollars in illegal kickbacks to US doctors between ...

Long-acting injectable antiretroviral therapy (ART) can be administered at home to persons living with HIV as safely and ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

Gilead held dinners to promote its HIV medications at expensive restaurants that federal authorities claim were “wholly inappropriate” venues, Stat reported. Gilead said it settled to avoid the cost ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...